immunitybio inc ibrx : nasdaq export watchlist + rt quote | last nasdaq ls, vol from cta | usd after hours: last | 4:53 pm edt 2.98 -0.07 ( -2.23% ) volume 61,409 close 3.05 +0.09 ( +3.04% ) volume 5,087,803 52 week range 2.28 - 10.53 summary news profile earnings peers ...
Get the latest ImmunityBio, Inc. (IBRX) stock news and headlines to stay up to date and make informed investing and trading decisions.
ImmunityBio, IncNEWS JOBS IN THE PRESS NEWS Layoffs ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung ...
The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financial analysts.
the options above, you agree to the terms of use & privacy policy bull or bear, seeking alpha is there markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. create free account ibrx immunitybio, inc. stock price & overview follow $ ...
在其他近期新闻中,ImmunityBio, Inc.因几项重要进展而成为头条。公司披露了新的高管薪酬安排,包括为Patrick Soon-Shiong博士和CEO Richard Adcock等高管提供的现金奖金和股权奖励。这些奖金是公司2024年高管激励薪酬计划的一部分,将于2025年3月支付。此外,ImmunityBio宣布董事会成员John Owen Brennan辞职,公司表示这与其运营...
這位分析師表示,儘管許多人都在關注CG Oncology Inc.(納斯達克股票代碼:CGON)的cretostimogene和強生(NYSE:JNJ)TAR-200在NMIBC市場上的競爭,但Anktiva在這個潛在價值超過50億美元的市場上以先發優勢脫穎而出。 「最終,我們相信ANKTIVA的概況加上給藥的簡便性將比對未經批准的產品在不同時間點的完全緩解率(CR)的...
ImmunityBio公布高管薪酬最新调整方案IBRX 5.22% 根据最近向美国证券交易委员会(SEC)提交的8-K文件显示,市值23.7亿美元的生物制品公司ImmunityBio, Inc. (NASDAQ:IBRX)已公布其高管的最新薪酬安排。 尽管该公司目前流动比率为2.68,保持较强的流动性,但根据InvestingPro分析显示,公司在过去12个月中EBITDA为负3.413亿美元...
2.47-0.01(-0.40%)USD | NASDAQ | Apr 17, 16:00 2.48+0.01(+0.40%)After-Hours: 20:00 Financials With YCharts’ financial data, you can comprehensively analyze companies’ Income Statements, Cash Flow Dynamics, and Balance Sheets. Harness these vital insights to unveil profitability trends, under...
2021年5月19日/医麦客新闻 eMedClub News/--近日,临床阶段免疫疗法公司ImmunityBio,Inc.宣布,已经获得美国FDA授权,可以进行一项1期临床研究以评估m-ceNK™平台结合其IL-15超激动剂Anktiva(N-803)用于患有局部晚期或转移性实体瘤患者的安全...